Business
Appointment of Nominated Adviser & TVR
Avacta Group PLC has appointed Strand Hanson Limited as its Nominated Adviser, effective immediately, and has corrected its total voting rights to 440,415,495 Ordinary Shares. The company also disclosed additional information regarding director Richard Hughes's past directorships in three companies that subsequently entered administration and were dissolved, with estimated creditor liabilities of £5.4 million, £0.1 million, and £0.5 million respectively. Disclaimer*
About this update from Avacta Group Plc
Appointment of Nominated Adviser Total Voting Rights Update LONDON and PHILADELPHIA - January 20, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, announces the appointment of Strand Hanson Limited as the Company's Nominated Adviser, with immediate effect. Correction to Total Voting Rights The Company's issued ordinary share capital is 440,415,495 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. Additional information is disclosed below under Schedule Two, paragraph (g) of the AIM Rules for Companies. -Ends- For further information from Avacta, please contact: Avacta Group plc Christina Coughlin, Chief Executive Officer https://avacta.com/ via ICR Healthcare Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance www.strandhanson.co.uk Zeus (Broker) James Hornigold / George Duxberry / Dominic King www.zeuscapital.co.uk ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert [email protected] Investor Contact Renee Leck THRUST Strategic Communications [email protected] Media Contact Carly Scaduto THRUST Strategic Communications [email protected] AIM Rule 17 Updates In addition to the disclosures made in the announcement of Richard Hughes's appointment to the Board on 28 May 2025, Richard Hughes was: appointed a director of Trafford Finance Limited on 28 October 2009, a company incorporated in England and Wales. The company was placed into administration on 21 April 2010 and was subsequently dissolved on 19 September 2013, with an estimated £5.4 million owed to creditors; appointed a director of Procurasell International (Packaging) Ltd on 30 October 2007, a company incorporated in England and Wales. The company was placed into administration on 8 January 2009 and was subsequently dissolved on 23 September 2010, with approximately £0.1 million owing to creditors; and appointed a director of Holyrood Leisure Limited on 26 April 2007, a company incorporated in England and Wales. The company was placed into administration on 28 June 2018 and was subsequently dissolved on 25 February 2020, with approximately £0.5 million owing to creditors. About Avacta - www.avacta.com Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION ® platform. pre|CISION ® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION ® peptide drug conjugates (PDC) or Affimer ® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. The pre|CISION ® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION ® platform harnesses this tumor specific protease to cleave pre|CISION ® peptide drug conjugates and pre|CISION ® antibody/Affimer ® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.